Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
ConditionPruritis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAkron Children's Hospital
About this trial
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Currently taking Dupixent for any other diagnosis
known allergy to Dupixent
pregnant and or lactating mothers
anyone treated for pruritus using laser therapy
Trial design
Design model
Parallel
Treatments tested in this trial
Dupilumab
Druginjection every two weeks while on study
Placebo
Other interventioninjection every two weeks while on study
Treatment groups
46 Participants
are divided into 2 treatment groupsGroup A: ARM 1 - DupixentActive comparator 1 intervention
Group B: ARM 2 - PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Itch Severity Scale (ISS) Scores
Participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent
Time frame
12 WEEKSSponsors and contacts
Click on the lead sponsor to view all of their trials.
Akron Children's Hospital
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
Ohio State University
Collaborator
Source ClinicalTrials.gov